What happens when PCAC says yes / no / abstain

Background

When PCAC votes on whether a bulk drug substance — for example, BPC-157, TB-500, or MOTs-C at the upcoming July 23-24, 2026 meeting — should be included on the 503A bulks list, the count is recorded as a number of “yes,” “no,” and “abstain” votes. These vote tallies are widely reported in trade press and on social media as if they decided a substance’s regulatory fate. They do not. PCAC is an advisory committee, and its votes are recommendations only.

This page summarizes what each PCAC outcome means in practice and what comes next inside FDA after the meeting closes.

What PCAC actually decides

Per the FDA’s PCAC web page, the committee provides advice on scientific, technical, and medical issues concerning drug compounding and makes recommendations to the Commissioner (FDA PCAC page). The vote on each nominated bulk drug substance is structured as a yes/no/abstain question on a specific motion drafted by FDA staff — typically whether the substance “should be included on the 503A bulks list.”

The committee’s vote is non-binding. The Commissioner of Food and Drugs (or the agency designee) decides whether to act on the advice. FDA, by statute, is the final arbiter for inclusion or exclusion from the 503A bulks list.

”Yes” vote

When a majority of voting members votes yes, FDA review staff documented in past minutes that the agency will take the recommendation under advisement and proceed toward proposed rulemaking. A yes vote does not, on its own, place the substance on the 503A bulks list. The substance still must be added through notice-and-comment rulemaking — FDA must publish a proposed rule in the Federal Register, accept comments, and then issue a final rule. Until a final rule is published, the substance’s compounding status is governed by FDA’s interim policy (FDA bulk substances under 503A page).

A yes vote also does not reverse a substance’s placement in Category 2 of the interim policy, which is a separate administrative determination. A peptide can be the subject of a positive PCAC recommendation while still sitting in Category 2 pending the agency’s final rule.

”No” vote

A no-majority vote is a recommendation that the substance not be added to the 503A bulks list. Historically, FDA has followed PCAC’s no recommendations in subsequent rulemaking, but the agency is not bound to do so. A no vote also does not, on its own, prohibit compounding. It is recommendation-level input that informs the eventual final rule. As FDA’s bulk-substances reference notes, the agency considers PCAC input alongside the broader administrative record when deciding whether to include a substance (FDA bulk substances page).

For peptides currently in Category 2, a no vote at PCAC would, in practice, signal that the substance is unlikely to leave Category 2 unless new safety or effectiveness data emerges in the rulemaking docket.

”Abstain”

An abstention does not count as either a yes or a no, but it is recorded in the meeting minutes against the member’s name. Abstentions sometimes reflect a member’s concern that the question as worded does not address the underlying safety or evidence issue, or that the data presented is insufficient for a confident vote. In practice, abstentions are a signal to FDA review staff that the question may need to be re-presented at a later meeting with additional data.

What FDA does next

After PCAC closes, FDA’s Office of Compounding Quality and Compliance prepares a recommendation memo to the Commissioner, then drafts the proposed rule that amends the 503A bulks list. The proposed rule is published in the Federal Register, where the public — including the original nominator, compounding pharmacies, peptide manufacturers, patient groups, and industry trade associations — may submit comments during a defined comment period. FDA reviews the comments and then publishes a final rule, which is the binding regulatory action.

The agency’s final rule may agree with PCAC, reject PCAC’s recommendation, or adopt a modified position (for example, listing only certain salt forms or restricting the route of administration). STAT News reported in April 2026 that the agency was preparing for the July 23-24 meeting against a backdrop of public political pressure to expand access to compounded peptides (STAT News, April 15, 2026).

Practical implications for a substance under review

For a peptide such as BPC-157, TB-500, or MOTs-C, the practical regulatory state on July 24, 2026 — the day after the PCAC vote — will be unchanged from the day before the meeting. The substance’s compounding status under the interim policy (FDA Category 2 reference) will remain in effect until FDA issues a proposed rule, accepts comments, and publishes a final rule. PCAC votes set direction; rulemaking sets law.